Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes

References

• American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl. 1):S1-S35
   Google Scholar
• Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22:935-42
   PubMed Web of Science ®Google Scholar
• Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75
   PubMed Web of Science ®Google Scholar
• Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-15
   PubMed Web of Science ®Google Scholar
• Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643-50
   PubMed Web of Science ®Google Scholar
• Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004;54:495-502
   PubMed Web of Science ®Google Scholar
• Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009-16
   PubMed Web of Science ®Google Scholar
• Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005;3:717-25
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16:1171-85
   PubMed Web of Science ®Google Scholar
• Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-50
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60
   PubMed Web of Science ®Google Scholar
• Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553-9
   PubMed Web of Science ®Google Scholar
• Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-80
   PubMed Web of Science ®Google Scholar
• Ricci J, Jhingran P, Harris W. Impact of differences in severity of irritable bowel syndrome (IBS) on patients' well being and resource use [abstract 2079]. Gastroenterology 2001;120(Suppl.):A406
   Google Scholar
• Lacy BE. Irritable bowel syndrome and disease severity: are we undertreating our patients? Expert Rev Gastroenterol Hepatol 2010;4:1-3
   PubMed Web of Science ®Google Scholar
• Miller D, Bennett L, Hollis K, et al. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther 2006;24:869-78
   PubMed Web of Science ®Google Scholar
• International Foundation for Functional Gastrointestinal Disorders. IBS in the Real World survey. Summary findings. International Foundation for Functional Gastrointestinal Disorders. Available at: http://aboutconstipation.org/pdfs/IBSRealWorld.pdf [Last accessed 1 September 2009]
   Google Scholar
• Williams RE, Black CL, Kim HY, et al. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1667-75
   PubMed Web of Science ®Google Scholar
• Thompson WG. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78-82
   PubMed Web of Science ®Google Scholar
• Lacy BE, Rosemore J, Robertson D, et al. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 2006;41:892-902
   PubMed Web of Science ®Google Scholar
• Palsson OS, Feld AD, Levy RL, et al. Comparison of irritable bowel syndrome (IBS) patients in gastroenterology and primary care clinics [abstract 122]. Gastroenterology 2003;124(4 Suppl. 1):A14
   Web of Science ®Google Scholar
• Charapata C, Mertz H. Physician knowledge of Rome symptom criteria for irritable bowel syndrome is poor among non-gastroenterologists. Neurogastroenterol Motil 2006;18:211-16
   PubMed Web of Science ®Google Scholar
• Dhaliwal SK, Hunt RH. Doctor–patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur J Gastroenterol Hepatol 2004;16:1161-6
   PubMed Web of Science ®Google Scholar
• Dalton CB, Drossman DA, Hathaway JM, et al. Perceptions of physicians and patients with organic and functional gastrointestinal diagnoses. Clin Gastroenterol Hepatol 2004;2:121-6
   PubMed Web of Science ®Google Scholar
• Lacy BE, Weiser K, De Lee R. Review: The treatment of irritable bowel syndrome. Ther Adv Gastroenterol 2009;2:221-38
   PubMedGoogle Scholar
• Adeniji OA, Barnett CB, Di Palma JA. Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig Dis Sci 2004;49:572-4
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Spiegel BMR, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A vignette-based survey of IBS experts versus non-experts [abstract 770]. Gastroenterology 2006;130:A-111
   Google Scholar
• Lea R, Hopkins V, Hastleton J, et al. Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion 2004;70:210-13
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995;40:986-95
   PubMed Web of Science ®Google Scholar
• Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402
   PubMed Web of Science ®Google Scholar
• Lacy B, Everhart K, Weiser K, et al. Medication risk taking behavior in IBS patients [abstract; program no. 1310]. Presented at: American College of Gastroenterology 2009 Annual Scientific Meeting, October 23–28, 2009, San Diego, CA, USA
   Google Scholar
• Spiegel BM, Bolus RE, Harris LA, et al. Patient-reported symptom relief from current therapy is a robust marker of illness severity in IBS [abstract 865]. Presented at Digestive Disease Week 2010, May 1–5, 2010, New Orleans, LA, USA
   Google Scholar
• Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40
   PubMed Web of Science ®Google Scholar
• Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-203
   PubMed Web of Science ®Google Scholar
• Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19
   PubMed Web of Science ®Google Scholar
• Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004;2:675-82
   PubMed Web of Science ®Google Scholar
• Nicandro JPA, Shin P, Shringarpure R, et al. Alosetron is associated with improvements in treatment satisfaction and quality of life [abstract M1058]. Presented at: Digestive Disease Week 2010, May 1–5, 2010, New Orleans, LA, USA
   Google Scholar
• Prometheus Laboratories I. Lotronex (alosetron hydrochloride) tablets [package insert]. San Diego, CA: Prometheus Laboratories Inc. 2008
   Google Scholar
• Nicandro JPA, Tennis P, Shin P, et al. One-year treatment continuation with alosetron is high irrespective of IBS-D severity [abstract T1064]. Presented at: Digestive Disease Week 2010, May 1–5, 2010, New Orleans, LA, USA
   Google Scholar
• Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:455-9
   PubMed Web of Science ®Google Scholar
• Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002;97:3139-46
   PubMed Web of Science ®Google Scholar
• Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol 2010;4:13-29
   PubMed Web of Science ®Google Scholar
• Gunput MD. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999;13(Suppl. 2):70-6
   PubMedGoogle Scholar
• Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34
   PubMed Web of Science ®Google Scholar
• Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59
   PubMed Web of Science ®Google Scholar
• Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-79
   PubMed Web of Science ®Google Scholar
• Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010;105:866-75
   PubMed Web of Science ®Google Scholar
• Cole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004;99:486-91
   PubMed Web of Science ®Google Scholar
• The iPledge Program Patient Introductory Brochure. Available at: www.ipledgeprogram.com [Last accessed 30 April 2010]
   Google Scholar